Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2961529 | 0.81 | — | — | |
| SCHEMBL704879 | 0.80 | IDO1 (0.54) | ALDH1A1GFERSMN1; SMN2TSHRRAB9A | |
| SCHEMBL491311 | 0.80 | AHR (0.41) | CYP1A2POLB | |
| SCHEMBL1774400 | 0.78 | ALPL (0.46) | ALDH1A1SMN1; SMN2CYP1A2POLBRAB9A | |
| SCHEMBL13239549 | 0.78 | IKBKB (0.33) | — | |
| SCHEMBL6176506 | 0.78 | TPMT (0.30) | — | |
| SCHEMBL6741105 | 0.74 | NOTUM (0.36) | POLBSLC9A1 | |
| SCHEMBL6160731 | 0.74 | USP2 (0.34) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL12496639 | 0.74 | PTK2 (0.32) | — | |
| SCHEMBL2028396 | 0.74 | ADH5 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932595-B2 | VDR-silent vitamin D derivative as inhibitors of SREBP and pharmaceutical use thereof | KYOTO UNIVERSITY, NATIONAL UNIVERSITY CORPORATION TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY, TEIKYO UNIVERSITY and THE UNIVERSITY OF TOKYO (JP) | 2024-03-19 | — | — | US | disclosed |
| WO-2022061193-A1 | VDR-SILENT VITAMIN D DERIVATIVE AS INHIBITORS OF SREBP AND PHARMACEUTICAL USE THEREOF | KYOTO UNIVERSITY (JP) | 2022-03-24 | — | — | WO | disclosed |
| US-20220081381-A1 | VDR-SILENT VITAMIN D DERIVATIVE AS INHIBITORS OF SREBP AND PHARMACEUTICAL USE THEREOF | KYOTO UNIVERSITY (JP) | 2022-03-17 | — | — | US | disclosed |
| US-8124584-B2 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20090304629-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | MIAO ZHENWEI | 2009-12-10 | — | — | US | disclosed |
| US-7601709-B2 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| EP-1590442-A4 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2007-07-18 | — | — | EP | disclosed |
| EP-1590442-A3 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2005-11-03 | — | — | EP | disclosed |
| EP-1590442-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20050153877-A1 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| WO-2004072243-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| US-4647572-A | Iodoallyl and iodopropargyl substituted tetrazoles and anti-microbial compositions thereof | MEIJI SEIKA KAISHA, LTD. (JP) | 1987-03-03 | — | — | US | disclosed |
| EP-0107859-A1 | Tetrazole compounds, process for preparing the same and antibacterial and antifungal compositions containing the same as active ingredient | MEIJI SEIKA KAISHA LTD. (JP) | 1984-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153877-A1 | Macrocyclic hepatitis C serine protease inhibitors | PRSS1, SPINT2, TMPRSS4 | ALDH1A1 1465/4885GFER 1438/4885RXFP1 4511/4885 |
| US-11932595-B2 | VDR-silent vitamin D derivative as inhibitors of SREBP and pharmaceutical use thereof | VDR, CYP24A1, CYP2R1 | ALDH1A1 1834/4885GFER 1682/4885RXFP1 1182/4885 |
| US-20220081381-A1 | VDR-SILENT VITAMIN D DERIVATIVE AS INHIBITORS OF SREBP AND PHARMACEUTICAL USE THEREOF | VDR, CYP24A1, CYP2R1 | ALDH1A1 1834/4885GFER 1682/4885RXFP1 1182/4885 |
| US-20090304629-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, TMPRSS4 | ALDH1A1 1430/4885GFER 1468/4885RXFP1 4508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.